Merck has shipped around 6.4 million courses of Lagevrio around the world to date, showing strong demand outside the US, but is expecting sales of the drug going forward to be weaker than expected.

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, N.J. – Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania ...

lower sales of the COVID-19 medication LAGEVRIO, lower sales of GARDASIL/GARDASIL 9 and lower sales of SIMPONI and REMICADE, reflecting the transfer of marketing rights in former Merck territories ...

Merck & Co., Inc. operates as a healthcare company ... and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting ...

Merck MRK reported fourth-quarter 2024 adjusted ... million compared with $149 million in the previous quarter. Sales of Lagevrio (molnupiravir) declined 37% to $121 million in the quarter.

The underlying core business looks solid, with operational sales growth of 8% (excluding Lagevrio), led by cancer drug Keytruda (up 17%). Merck’s steady pipeline innovation, especially the ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Davis, chairman and chief executive officer, Merck. "We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development.

(1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue ...